Treatment of idiopathic interstitial pneumonias

Authors: Corte, Tamera J; Wells, Athol U

Source: Expert Review of Respiratory Medicine, Volume 3, Number 1, February 2009 , pp. 81-91(11)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

The idiopathic interstitial pneumonias can be grouped, for treatment purposes, into primary inflammatory disorders, fibrotic nonspecific interstitial pneumonia (in which inflammation is thought to precede and progress to fibrosis) as well as the most common of the idiopathic interstitial pneumonia subgroups, idiopathic pulmonary fibrosis. Over the past decade, there have been several paradigm shifts in the understanding of idiopathic interstitial pneumonias and their treatment. In particular, we highlight changes in the use of prognostic markers, clinical trial end points and the understanding of pathogenesis of idiopathic pulmonary fibrosis. We outline a practical approach to the treatment of these three patient groups.

Keywords: anti-inflammatory; antioxidant; corticosteroid; idiopathic interstitial pneumonia; idiopathic pulmonary fibrosis; immunosuppressants; N-acetyl-cysteine; prognosis; treatment

Document Type: Research article

DOI: http://dx.doi.org/10.1586/17476348.3.1.81

Affiliations: 1: Clinical Research Fellow, Department of Interstitial Lung Disease, Royal Brompton Hospital, Sydney Street, London, SW3 6NP, UK., Email: t.corte@rbht.nhs.uk

Publication date: 2009-02-01

More about this publication?

Expert Review of Respiratory Medicine provides an authoritative and focused forum for commentary and analysis for those involved in all areas of pulmonary medicine.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
Free Trials
ingentaconnect is not responsible for the content or availability of external websites